Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

PubMed Links for Books (Select 2829292)

1.

Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia.

FIGO Committee on Gynecologic Oncology.

Int J Gynaecol Obstet. 2009 Apr;105(1):3-4. No abstract available.

PMID:
19322933
2.

Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment.

Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, Savage PM, Newlands ES, Rustin GJ, Seckl MJ.

J Clin Oncol. 2006 Oct 20;24(30):4862-6.

3.
4.

Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors.

Mandanas RA, Saez RA, Epstein RB, Confer DL, Selby GB.

Bone Marrow Transplant. 1998 Mar;21(6):569-76.

5.

Surveillance policy for stage I ovarian germ cell tumors.

Dark GG, Bower M, Newlands ES, Paradinas F, Rustin GJ.

J Clin Oncol. 1997 Feb;15(2):620-4.

PMID:
9053485
6.

Update on malignant ovarian germ cell tumors.

Gershenson DM.

Cancer. 1993 Feb 15;71(4 Suppl):1581-90. Review.

PMID:
8381708
7.

Second-look laparotomy in ovarian germ cell tumors: the gynecologic oncology group experience.

Williams SD, Blessing JA, DiSaia PJ, Major FJ, Ball HG 3rd, Liao SY.

Gynecol Oncol. 1994 Mar;52(3):287-91.

PMID:
8157184
8.

The obsolescence of second-look laparotomy in the management of malignant ovarian germ cell tumors.

Gershenson DM.

Gynecol Oncol. 1994 Mar;52(3):283-5. No abstract available.

PMID:
8157183
9.

Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience.

Segelov E, Campbell J, Ng M, Tattersall M, Rome R, Free K, Hacker N, Friedlander ML.

J Clin Oncol. 1994 Feb;12(2):378-84.

PMID:
8113845
10.

Salvage surgery for chemorefractory ovarian germ cell tumors.

Munkarah A, Gershenson DM, Levenback C, Silva EG, Messing MJ, Morris M, Burke TW.

Gynecol Oncol. 1994 Nov;55(2):217-23.

PMID:
7959287
11.

Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group.

Williams S, Blessing JA, Liao SY, Ball H, Hanjani P.

J Clin Oncol. 1994 Apr;12(4):701-6.

PMID:
7512129
12.

Current therapy for dysgerminoma of the ovary.

Thomas GM, Dembo AJ, Hacker NF, DePetrillo AD.

Obstet Gynecol. 1987 Aug;70(2):268-75. Review.

PMID:
3299187
13.

Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report).

Slayton RE, Park RC, Silverberg SG, Shingleton H, Creasman WT, Blessing JA.

Cancer. 1985 Jul 15;56(2):243-8.

PMID:
2988740
14.

Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group.

Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L.

Ann Intern Med. 1989 Jul 1;111(1):22-7.

PMID:
2472080
15.

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.

Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ.

N Engl J Med. 1987 Jun 4;316(23):1435-40.

PMID:
2437455
16.
17.

Vinblastine, bleomycin, and cisplatin in malignant germ cell tumors of the ovary.

Taylor MH, Depetrillo AD, Turner AR.

Cancer. 1985 Sep 15;56(6):1341-9.

PMID:
2411377
18.

Treatment of malignant ovarian germ cell tumors with preservation of fertility: a report of 28 cases.

Wu PC, Huang RL, Lang JH, Huang HF, Lian LJ, Tang MY.

Gynecol Oncol. 1991 Jan;40(1):2-6.

PMID:
1846603
19.

Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group.

Williams SD, Blessing JA, Hatch KD, Homesley HD.

J Clin Oncol. 1991 Nov;9(11):1950-5.

PMID:
1719142
20.

Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin.

Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, Silva EG, Wharton JT.

J Clin Oncol. 1990 Apr;8(4):715-20.

PMID:
1690272
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk